Dr. Stella Sarraf founded Spinogenix in 2016 to focus on developing novel neuroregenerative therapeutics. She brings a blend of large pharmaceutical operational expertise, venture investment background and entrepreneurship to Spinogenix. Dr. Sarraf is viewed as a visionary with a deep understanding of “cradle to grave” and the necessary components to achieve success from product concept through to commercialization. In 2013, she founded Amydis, a privately held clinical stage company focused on developing a new class of ocular tracers to enable digital detection and monitoring of neurodegenerative disease to accelerate diagnosis, improve the clinical testing of novel therapeutics and revolutionize treatment in people. 

Previously, she spent 10 years in Venture Capital at Foresite Capital Management and Prospect Venture Partners, growth capital healthcare funds with over billions in assets under management. Earlier in her career, Dr. Sarraf worked at Merck Research Laboratories in Rahway, New Jersey as a senior research chemist responsible for creating the chemical synthesis of a novel drug for translation from the bench to production scale. Dr. Sarraf holds a PhD in organic chemistry from Columbia University and earned a BA in biochemistry and molecular biology from the University of California, Berkeley.